DarioHealth Corp.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
DRIO$2.06-13.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| No. | Description of Exhibit | |
| 3.1 | | Certificate of Amendment to the Company’s Certificate of Incorporation to implement the Reverse Stock Split, dated August 25, 2025 (incorporated by reference to Exhibit 3.1 filed with the Company’s Current Report on Form 8-K filed on August 25, 2025). |
| 3.2 | | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.1 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.3 | | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.2 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.4 | | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C-2 Preferred Stock of DarioHealth Corp.(incorporated by reference to Exhibit 3.3 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.5 | | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.4 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.6 | | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.5 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.7 | | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D-2 Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.6 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.8 | | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series D-3 Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.7 filed with the Company’s Current Report on Form 8-K filed on September 19, 2025). |
| 3.9 | | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C-1 Preferred Stock of DarioHealth Corp. (incorporated by reference to Exhibit 3.1 filed with the Company’s Current Report on Form 8-K filed on September 25, 2025). |
| 4.1 | | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 filed with the Company’s Current Report on Form 8-K filed on September 25, 2025). |
| 4.2˄ | | Form of Warrant Amendment (incorporated by reference to Exhibit 4.1 filed with the Company’s Current Report on Form 8-K filed on November 10, 2025). |
| 10.1 | | Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on September 25, 2025). |
| 10.2* | | Form of Second Amended and Restated Lock-Up Agreement. |
| 10.3˄ | | First Amendment to Credit Agreement, dated November 5, 2025, by and among the Company, as borrower, Callodine Commercial Finance, LLC, as agent and lender, and the financial institutions party thereto from time to time as lenders (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on November 10, 2025). |
| 31.1* | | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a). |
| 31.2* | | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a). |
| 32.1** | | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350. |
| 32.2** | | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350. |
| 101.1* | | The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Statements of Changes in Stockholders’ Deficiency, (iv) Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail. |
| 104 | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |
| | | |
*Filed herewith.
**Furnished herewith.
| ˄ | Certain identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to DarioHealth Corp. if publicly disclosed. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.